AbCellera Sets Q2 2026 Earnings Date—Clinical-Stage Pipeline Remains in Focus
Market Chameleon (Wed, 8-Jul 3:06 AM ET)
AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026
Business Wire (Tue, 7-Jul 4:05 PM ET)
AbCellera Appoints Dr. Lynn Seely to its Board of Directors
Business Wire (Mon, 6-Jul 9:00 AM ET)
For Life Sciences AI, Data Is the New Moat: MindWalk’s Patent Filing Spotlights Industry Shift
Market Chameleon (Wed, 1-Jul 5:22 AM ET)
PRNewswire (Wed, 1-Jul 9:01 AM ET)
Market Chameleon (Wed, 17-Jun 3:29 AM ET)
Business Wire (Wed, 17-Jun 7:00 AM ET)
AbCellera Appoints Dr. Victor Sandor to its Board of Directors
Business Wire (Fri, 5-Jun 9:00 AM ET)
Business Wire (Mon, 11-May 4:05 PM ET)
AbCellera to Present at Upcoming Investor Conferences in May and June 2026
Business Wire (Thu, 7-May 4:05 PM ET)
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
Abcellera Biologics - Common Shares trades on the NASDAQ stock market under the symbol ABCL.
As of July 23, 2026, ABCL stock price declined to $5.67 with 2,590,056 million shares trading.
ABCL has a beta of 2.60, meaning it tends to be more sensitive to market movements. ABCL has a correlation of 0.13 to the broad based SPY ETF.
ABCL has a market cap of $1.73 billion. This is considered a Small Cap stock.
Last quarter Abcellera Biologics - Common Shares reported $8 million in Revenue and -$.14 earnings per share. This beat revenue expectation by $3 million and exceeded earnings estimates by $.06.
In the last 3 years, ABCL traded as high as $8.44 and as low as $1.89.
The top ETF exchange traded funds that ABCL belongs to (by Net Assets): IBB, CPAI, SPDW, IDNA, GWX.
ABCL has underperformed the market in the last year with a price return of +15.2% while the SPY ETF gained +18.6%. However, in the short term, ABCL had mixed performance relative to the market. It has outperformed in the last 3 months, returning +39.0% vs +4.1% return in SPY. But in the last 2 weeks, ABCL shares have been beat by the market, returning -20.1% compared to an SPY return of -1.0%.
ABCL support price is $5.37 and resistance is $6.10 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABCL shares will trade within this expected range on the day.